Trial Profile
A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Delpazolid (Primary) ; Linezolid; Rifampicin/isoniazid/pyrazinamide/ethambutol
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Sponsors LegoChem Biosciences
- 06 Dec 2021 Results assessing the bactericidal activity, safety, and pharmacokinetics of delpazolid in patients with pulmonary tuberculosis (TB) published in the Antimicrobial Agents and Chemotherapy
- 04 Feb 2020 Status changed from recruiting to completed.
- 14 Aug 2019 Planned End Date changed from 1 Dec 2018 to 1 Feb 2020.